The Institute of Cancer Research

(IN BRIEF) Researchers from The Institute of Cancer Research and The University of Manchester have created the most comprehensive map of cancer-related genetic mutations to date, analysing data from nearly 11,000 patients in the 100,000 Genomes Project. The study identified … Read the full press release →

(IN BRIEF) Scientists at the Institute of Cancer Research in London are contributing to an international clinical trial evaluating THEO-260, an experimental oncolytic immunotherapy designed to treat platinum-resistant ovarian cancer. The trial, known as OCTOPOD-IV, is being supported by €8 … Read the full press release →

(IN BRIEF) Researchers at The Institute of Cancer Research, London have created a next-generation PROTAC degrader that successfully eliminates the cancer-related protein Aurora A while overcoming the hook effect that has limited earlier degraders. The new molecule, CCT400028, demonstrates improved … Read the full press release →

(IN BRIEF) Researchers at The Institute of Cancer Research, London, have found that the precise location of ATRX gene mutations plays a critical role in determining how neuroblastoma tumours behave and respond to treatment. Published in Neoplasia and supported by … Read the full press release →

(IN BRIEF) The Institute of Cancer Research, London has appointed Dr Michelle Harrison to its Board of Trustees, bringing extensive experience in global public policy, corporate leadership, and charity governance to the organisation’s governing body. A former Chief Executive and … Read the full press release →

(IN BRIEF) Researchers at The Institute of Cancer Research, London, have uncovered how the DNA repair enzyme XPF-ERCC1 is recruited to sites of damage and activated inside cells, resolving a long-standing question in molecular biology and providing structural insights that … Read the full press release →

(IN BRIEF) The Institute of Cancer Research has welcomed Sutton Council’s approval of ambitious plans led by Aviva Capital Partners and Socius to create around one million square feet of new life-sciences research and laboratory space across a 12-acre site … Read the full press release →

(IN BRIEF) The Institute of Cancer Research, London, has led the development of OPTIMISE-ROR, the first structured guidance outlining how patient-reported outcomes should be used in early-stage cancer dose-finding trials. Published in the Journal of Clinical Oncology, the recommendations provide … Read the full press release →

(IN BRIEF) The Institute of Cancer Research has welcomed NICE’s recommendation of talazoparib in combination with enzalutamide for adults with metastatic prostate cancer, providing a new treatment option for around 2,400 patients in England who are unsuitable for chemotherapy. Backed … Read the full press release →

(IN BRIEF) Researchers at the Institute of Cancer Research and St Mark’s Hospital are launching a major study analysing historic bowel cancer samples dating back more than 70 years to understand why diagnoses are rising in people under 50. By … Read the full press release →

(IN BRIEF) The Institute of Cancer Research has led a study showing that chromosomal instability in circulating tumour cells can predict resistance to cabazitaxel in men with advanced prostate cancer. Using blood samples from more than 200 patients enrolled in … Read the full press release →

(IN BRIEF) Researchers at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust have developed AI software that automates the complex interpretation of whole-body diffusion-weighted MRI scans, which are increasingly used to evaluate advanced prostate cancer. The … Read the full press release →

(IN BRIEF) The Institute of Cancer Research, London, has announced the launch of the £42 million TRANSFORM trial, the UK’s largest prostate cancer screening study in more than 20 years. The first men have now been invited by their GPs … Read the full press release →

(IN BRIEF) Researchers at The Institute of Cancer Research, London, have achieved a breakthrough in the treatment of advanced sarcoma and melanoma through a novel combination of isolated limb perfusion (ILP) and oncolytic virus therapy. In the first clinical trial … Read the full press release →

(IN BRIEF) The Phase III RAMPART trial has demonstrated that combining the immunotherapy drugs durvalumab and tremelimumab after surgery significantly improves disease-free survival in patients with early-stage renal cell carcinoma (RCC). Led by the Medical Research Council Clinical Trials Unit … Read the full press release →

(IN BRIEF) Long-term data from the international monarchE trial has confirmed that patients with HR+ and HER2- node-positive high-risk early breast cancer achieve better survival outcomes when treated with the targeted therapy abemaciclib in combination with standard hormone therapy. Presented … Read the full press release →

(IN BRIEF) In recognition of World Statistics Day 2025, The Institute of Cancer Research (ICR), London, is spotlighting the essential role of statisticians in advancing cancer research through reliable, transparent, and responsible data analysis. The event, themed “Quality statistics and … Read the full press release →

(IN BRIEF) A new global analysis by The Institute of Cancer Research (ICR), London, has found that cancer incidence is rising in both younger and older adults, disputing the idea that the global increase is limited to those under 50. … Read the full press release →

(IN BRIEF) A new study led by researchers at The Institute of Cancer Research, London, has identified a promising new combination therapy for pancreatic cancer that could transform future treatment. The dual approach — combining boiling histotripsy and oncolytic reovirus … Read the full press release →

(IN BRIEF) The Institute of Cancer Research has renewed its Athena Swan Silver Award for 2025–2029, recognising continued progress in promoting gender equality and fostering an inclusive workplace. The award highlights key achievements such as improved recruitment and flexible working … Read the full press release →